Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000484086 | SCV000571162 | likely pathogenic | not provided | 2016-07-26 | criteria provided, single submitter | clinical testing | The c.90626delA variant in the TTN gene has not been reported previously as a pathogenic variant or as a benign variant, to our knowledge. This variant causes a shift in reading frame starting at codon Lysine 30209, changing it to an Arginine, and creating a premature stop codon at position 19 of the new reading frame, denoted p.Lys30209ArgfsX19. This variant is expected to result in either an abnormal, truncated protein product or loss of protein from this allele through nonsense-mediated mRNA decay. Other truncating TTN variants have been reported in approximately 3% of control alleles (Herman et al., 2012). However, c.90626delA is located in the A-band region of titin, where the majority of truncating pathogenic variants associated with dilated cardiomyopathy (DCM) have been reported (Herman et al., 2012). Other frameshift variants in the TTN gene have been reported in HGMD in association with DCM (Stenson et al., 2014). Furthermore, c.90626delA was not observed in approximately 6,200 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, c.90626delA in the TTN gene is expected to be pathogenic, as loss of function variants in this gene are strongly associated with this phenotype. |